Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Predictive Oncology Inc. (POAI) announced appointments to its board and leadership team to support a digital asset treasury strategy focused on the Aethir token.
The company appointed Shawn Matthews, CEO of DNA Holdings Venture Inc. and former CEO of Cantor Fitzgerald, to its board of directors. Thomas McLaughlin joined as chief investment officer and Sara Turken as general counsel.
Matthews served as CEO and president of Cantor Fitzgerald from 2009 to 2018, overseeing more than 100 affiliated entities across financial services and fintech businesses. He currently leads DNA Holdings Venture, which the company identifies as a PIPE investor, and founded Hondius Capital Management in 2019.
McLaughlin serves as chief investment officer of DNA Asset Management and previously founded Coral Capital, a crypto asset management firm with $125 million in assets under management. He began his career as an investment banking analyst at Bank of America Merrill Lynch.
Turken brings experience from biotechnology companies including Excision BioTherapeutics and Rocket Pharmaceuticals. She previously worked as a corporate associate at Covington & Burling and as an investment banking associate at Credit Suisse.
Predictive Oncology operates an AI-driven drug discovery platform and maintains a biobank of more than 150,000 tumor samples. The company describes itself as operating the world’s first Strategic Compute Reserve through its holdings of Aethir tokens, functioning as an operator on the Aethir ecosystem.
CEO Raymond Vennare stated the appointments align with the company’s digital treasury asset strategy, which he said addresses AI requirements while benefiting from global AI infrastructure demand.
The information is based on a company press release.